id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1300854,4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14,Q3,"TAKEDA PHARMACEUTICALS AMERICA, INC.",57954,TAKEDA PHARMACEUTICALS AMERICA INC,2012,third_quarter,TRD,"Counterfiet drugs, serialization and development of tracibility model","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2012-10-16T14:32:54.040000-04:00
1300855,4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14,Q3,"TAKEDA PHARMACEUTICALS AMERICA, INC.",57954,TAKEDA PHARMACEUTICALS AMERICA INC,2012,third_quarter,HCR,ACA implications of SCOTUS ruling,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2012-10-16T14:32:54.040000-04:00
1300856,4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14,Q3,"TAKEDA PHARMACEUTICALS AMERICA, INC.",57954,TAKEDA PHARMACEUTICALS AMERICA INC,2012,third_quarter,PHA,PDUFA,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2012-10-16T14:32:54.040000-04:00
1300857,4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14,Q3,"TAKEDA PHARMACEUTICALS AMERICA, INC.",57954,TAKEDA PHARMACEUTICALS AMERICA INC,2012,third_quarter,MMM,"Medicare reform; Product portfolio; depression drugs, CNS","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2012-10-16T14:32:54.040000-04:00
1300858,4e7e92c9-a03e-4d7f-9edc-2ba6d20d7a14,Q3,"TAKEDA PHARMACEUTICALS AMERICA, INC.",57954,TAKEDA PHARMACEUTICALS AMERICA INC,2012,third_quarter,BUD,Implications of deficit reduction,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,280000,0,0,2012-10-16T14:32:54.040000-04:00